Compare Cognizant Technology Solutions Corp (CTSH) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cognizant Technology Solutions Corp vs Vertex Pharmaceuticals Incorporated — how do they compare? Cognizant Technology Solutions Corp trades at $59.71 (market cap $25.71B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 5× Cognizant Technology Solutions Corp's market cap, and Cognizant Technology Solutions Corp pays a 2.31% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cognizant Technology Solutions Corp for 57 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| CTSH | VRTX | |
|---|---|---|
Market Cap | $25.71B | $128.16B |
Volume | 5,152,376 | 806,603 |
Sector | Technology | Health |
52-Week High | $86.70 | $557.96 |
52-Week Low | $38.73 | $407.37 |
Typical Hold Time | 57 Days | 120 Days |
Enterprise Value | $26.75B | $122.29B |
Dividend Yield | 2.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cognizant Technology Solutions (CTSH) trades at $60.01, up 4.88% on the day, with a bearish technical signal despite recent earnings beats. The stock shows solid fundamentals with a P/E of 12.25 and net income margin of 10.26%, while revenue grew to $21.11B in 2025. Analyst consensus is mixed with a $64.25 price target, and the company continues to gain recognition for AI-driven initiatives and workplace excellence.
CTSH presents a balanced outlook with undervalued metrics and strong cash flow, but faces headwinds from technical bearishness and competitive IT spending pressures. The upcoming Q3 2026 earnings on October 29, 2026, will be critical for confirming growth trajectory amid evolving AI integration strategies.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cognizant Technology Solutions Corp
Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.
Read more on CTSH →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
